デフォルト表紙
市場調査レポート
商品コード
453798

アルファアンチトリプシン欠乏症(AATD)- 市場分析、疫学、市場予測

Alpha Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 200 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
アルファアンチトリプシン欠乏症(AATD)- 市場分析、疫学、市場予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アルファアンチトリプシン欠乏症(AATD)は、体内で十分な量のAATタンパク質が生成されず、好中球エラスターゼなどのタンパク質分解酵素の有害な作用に臓器がさらされることで発症します。肝臓で作られるAATタンパク質は、肺などの臓器をタンパク質分解酵素から守るために重要な役割を果たしていますが、原因によってはタンパク質が血液中に入り込んで思うように働けなくなり、肺疾患のリスクを高めることになります。

DelveInsightによると、米国およびEU5ヶ国(ドイツ、スペイン、イタリア、フランス、英国)におけるアルファアンチトリプシン欠乏症(AATD)の有病者数は2017年には17万5,009人でした。この6カ国の市場規模は、2017年には6億9,800万米ドルでしたが、2030年までの間にさらに増加すると予測されています。

当レポートでは、米国およびEU5ヶ国(ドイツ、スペイン、イタリア、フランス、英国)のアルファアンチトリプシン欠乏症(AATD)市場の動向に加え、疫学の歴史と予測、疾患の詳細な分析を提供しています。また、アルファアンチトリプシン欠乏症(AATD)の治療法、新たな治療薬、それぞれの治療法の市場シェア、現在の市場規模と予測、現在の治療法/アルゴリズム、市場の推進要因、市場の障壁、アンメットニーズなどの情報も提供しています。

目次

第1章 主な洞察

第2章 アルファアンチトリプシン欠乏症の概要

第3章 アルファアンチトリプシン欠乏症のSWOT分析

第4章 アルファアンチトリプシン欠乏症の患者シェア

第5章 アルファアンチトリプシン欠乏症市場の概要

第6章 疾患の背景と概要

  • イントロダクション
  • 症状
  • 病因
  • 危険因子
  • AATDの遺伝的遺伝
  • 臨床症状
  • 病態生理
  • バイオマーカー
  • 診断
  • 診断の遅延

第7章 疫学と患者人口

  • 主な調査結果
  • 主要6カ国のアルファ1アンチトリプシン欠乏症患者数

第8章 国別のアルファ1アンチトリプシン欠乏症の疫学

  • 仮定と根拠
  • 米国
    • AATDの発症数
    • AATDと診断された患者数
    • AATD診断患者の遺伝子型
    • AATDに関連した併存疾患
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第9章 治療

  • 現在の治療法
    • 増強療法
    • 遺伝子治療
    • ライフスタイルの変化
    • 新しい治療法

第10章 治療アルゴリズム

  • 肺疾患を伴うアルファアンチトリプシン欠乏症の管理
  • 肝疾患を伴うアルファアンチトリプシン欠乏症の管理

第11章 アンメットニーズ

第12章 アルファアンチトリプシン欠乏症の治療に貢献している組織

第13章 事例報告

第14章 上市済み医薬品

  • Prolastin C: Grifols
  • Glassia: Kamada
  • Aralast: Shire
  • Zemaira:CSL Behring
  • Alfalastin: LFB Biotechnologies
  • Trypsone: Grifols

第15章 新たな治療法

  • Inhaled AAT (Glassia IH): Kamada Ltd
  • ALN-AAT02: Alnylam Pharmaceuticals
  • ARO-AAT: Arrow Head Pharmaceuticals
  • VX-814: Vertex Pharmaceuticals
  • Alvelestat (MPH-966): Mereo Biopharma
  • DCR-A1AT: Dicerna Pharmaceuticals

第16章 その他の有望な候補者

  • INBRX-101:Inhibrx
  • Carbamazepine: Novartis Pharmaceuticals
  • VX-864:Vertex Pharmaceuticals

第17章 アルファアンチトリプシン欠乏症:主要6市場の分析

  • AATDの合計市場規模

第18章 アルファアンチトリプシン欠乏症:国別の市場分析

  • 米国
    • AATDの合計市場規模
    • 米国の治療法別アルファアンチトリプシン欠乏症の市場規模
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第19章 アルファアンチトリプシン欠乏症に対するGrifolsの取り組み

第20章 アルファ1アンチトリプシン欠乏症(AATD)患者に対する米国FDAの取り組み

第21章 市場の推進力

第22章 市場の障壁

第23章 アルファアンチトリプシン欠乏症へのアクセスと償還の概要

第24章 付録

章25:DelveInsightのサービス内容

第26章 免責事項

章27:DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Alpha-1 Antitrypsin Deficiency (AATD) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Diagnostic Delay Interval for AATD
  • Table 3: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2017-2030)
  • Table 4: Prevalence of Symptomatic AATD in the United States (2017-2030)
  • Table 5: Diagnosed population of AATD in the United States (2017-2030)
  • Table 6: Genotype of AATD Diagnosed patients in the United States (2017-2030)
  • Table 7: Comorbidity associated with AATD in the United States (2017-2030)
  • Table 8: Prevalence of Symptomatic AATD in Germany (2017-2030)
  • Table 9: Diagnosed population of AATD in Germany (2017-2030)
  • Table 10: Genotype of AATD Diagnosed patients in Germany (2017-2030)
  • Table 11: Comorbidity associated with AATD in Germany (2017-2030)
  • Table 12: Prevalence of Symptomatic AATD in France (2017-2030)
  • Table 13: Diagnosed population of AATD in France (2017-2030)
  • Table 14: Genotype of AATD Diagnosed patients in France (2017-2030)
  • Table 15: Comorbidity associated with AATD in France (2017-2030)
  • Table 16: Prevalence of Symptomatic AATD in Italy (2017-2030)
  • Table 17: Diagnosed population of AATD in Italy (2017-2030)
  • Table 18: Genotype of AATD Diagnosed patients in Italy (2017-2030)
  • Table 19: Comorbidity associated with AATD in Italy (2017-2030)
  • Table 20: Prevalence of Symptomatic AATD in Spain (2017-2030)
  • Table 21: Diagnosed population of AATD in Spain (2017-2030)
  • Table 22: Genotype of AATD Diagnosed patients in Spain (2017-2030)
  • Table 23: Comorbidity associated with AATD in Spain (2017-2030)
  • Table 24: Prevalence of Symptomatic AATD in The United Kingdom (2017-2030)
  • Table 25: Diagnosed population of AATD in The United Kingdom (2017-2030)
  • Table 26: Genotype of AATD Diagnosed patients in The United Kingdom (2017-2030)
  • Table 27: Comorbidity associated with AATD in The United Kingdom (2017-2030)
  • Table 28: Organizations contributing toward Alpha-Antitrypsin Deficiency
  • Table 29: Inhaled AAT, Clinical Trial Description, 2020
  • Table 30: ALN-AAT02, Clinical Trial Description, 2020
  • Table 31: ARO-AAT, Clinical Trial Description, 2020
  • Table 32: VX-814, Clinical Trial Description, 2020
  • Table 33: Alvelestat, Clinical Trial Description, 2020
  • Table 34: DCR-A1AT, Clinical Trial Description, 2020
  • Table 35: INBRX-101, Clinical Trial Description, 2020
  • Table 36: Carbamazepine, Clinical Trial Description, 2020
  • Table 37: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 38: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 39: US Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
  • Table 40: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 41: Germany Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)
  • Table 42: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 43: France Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 44: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
  • Table 45: Italy Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 46: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017 -2030)
  • Table 47: Spain Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017-2030)
  • Table 48: Total Market Size of Alpha Antitrypsin Deficiency in USD Million (2017-2030)
  • Table 49: UK Market Size of Alpha Antitrypsin Deficiency by Products in USD, Million (2017 -2030)

List of Figures

FIGURE 1: SWOT ANALYSIS

FIGURE 2: HISTORICAL OVERVIEW OF AATD DEVELOPMENT

FIGURE 3: SYMPTOMS ASSOCIATED WITH ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 4: RISK FACTORS FOR AATD

FIGURE 5: INHERITANCE OF AATD

FIGURE 6: INHERITANCE PATTERN OF AATD

FIGURE 7: ALPHA-1 ANTITRYPSIN BINDS AND INACTIVATES NEUTROPHIL ELASTASE.

FIGURE 8: PATHOGENESIS OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 9: DIAGNOSTIC ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 10: ATS/ERS DIAGNOSTIC RECOMMENDATIONS FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 11: ATS/ERS RECOMMENDATIONS (TO BE DISCUSSED) FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 12: ATS/ERS DIAGNOSTIC RECOMMENDATIONS (NOT RECOMMENDED) FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 13: DIAGNOSTIC AND MONITORING METHODS FOR ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 14: TOTAL PREVALENT POPULATION OF ALPHA-1-ANTITRYPSIN DEFICIENCY IN 6 MM (2017-2030)

FIGURE 15: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED STATES (2017-2030)

FIGURE 16: DIAGNOSED POPULATION OF AATD IN THE UNITED STATES (2017-2030)

FIGURE 17: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED STATES (2017-2030)

FIGURE 18: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED STATES (2017-2030)

FIGURE 19: PREVALENCE OF SYMPTOMATIC AATD IN GERMANY (2017-2030)

FIGURE 20: DIAGNOSED POPULATION OF AATD IN GERMANY (2017-2030)

FIGURE 21: GENOTYPE OF AATD DIAGNOSED PATIENTS IN GERMANY (2017-2030)

FIGURE 22: COMORBIDITY ASSOCIATED WITH AATD IN GERMANY (2017-2030)

FIGURE 23: PREVALENCE OF SYMPTOMATIC AATD IN FRANCE (2017-2030)

FIGURE 24: DIAGNOSED POPULATION OF AATD IN FRANCE (2017-2030)

FIGURE 25: GENOTYPE OF AATD DIAGNOSED PATIENTS IN FRANCE (2017-2030)

FIGURE 26: COMORBIDITY ASSOCIATED WITH AATD IN FRANCE (2017-2030)

FIGURE 27: PREVALENCE OF SYMPTOMATIC AATD IN ITALY (2017-2030)

FIGURE 28: DIAGNOSED POPULATION OF AATD IN ITALY (2017-2030)

FIGURE 29: GENOTYPE OF AATD DIAGNOSED PATIENTS IN ITALY (2017-2030)

FIGURE 30: COMORBIDITY ASSOCIATED WITH AATD IN ITALY (2017-2030)

FIGURE 31: PREVALENCE OF SYMPTOMATIC AATD IN SPAIN (2017-2030)

FIGURE 32: DIAGNOSED POPULATION OF AATD IN SPAIN (2017-2030)

FIGURE 33: GENOTYPE OF AATD DIAGNOSED PATIENTS IN SPAIN (2017-2030)

FIGURE 34: COMORBIDITY ASSOCIATED WITH AATD IN SPAIN (2017-2030)

FIGURE 35: PREVALENCE OF SYMPTOMATIC AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 36: DIAGNOSED POPULATION OF AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 37: GENOTYPE OF AATD DIAGNOSED PATIENTS IN THE UNITED KINGDOM (2017-2030)

FIGURE 38: COMORBIDITY ASSOCIATED WITH AATD IN THE UNITED KINGDOM (2017-2030)

FIGURE 39: TREATMENT RECOMMENDATIONS FOR AATD

FIGURE 40: AVAILABLE THERAPEUTICS OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 41: STRATEGIES FOR DELIVERY OF ENGINEERED NUCLEASES: A) EX-VIVO ; B) IN VIVO

FIGURE 42:GENOME EDITING WITH ENGINEERED NUCLEASES

FIGURE 43: TREATMENT ALGORITHM OF ALPHA ANTITRYPSIN DEFICIENCY

FIGURE 44: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE

FIGURE 45: ALGORITHM FOR MANAGEMENT OF ALPHA ANTITRYPSIN DEFICIENCY WITH LUNG DISEASE

FIGURE 46: CURRENT UNMET NEEDS

FIGURE 47: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 48: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 49: US MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017 -2030)

FIGURE 50: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 51: GERMANY MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 52: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017-2030)

FIGURE 53: FRANCE MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 54: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2030)

FIGURE 55: ITALY MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY BY PRODUCTS IN USD, MILLION (2017-2030)

FIGURE 56: TOTAL MARKET SIZE OF ALPHA ANTITRYPSIN DEFICIENCY IN USD, MILLION (2017 -2030)

目次
Product Code: DIMI0001

DelveInsight's 'Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATD's in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)

Study Period: 2017-2030

Alpha Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

The DelveInsight Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

Alpha Antitrypsin Deficiency Epidemiology

The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017. 

Alpha Antitrypsin Deficiency Drug Chapters

This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended. However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors' plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60  mg/kg per week in order to achieve the protective level of AAT in serum.

Alpha Antitrypsin Deficiency Market Outlook

The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

Alpha Antitrypsin Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha Antitrypsin Deficiency Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alpha Antitrypsin Deficiency Report Key Strengths

  • 11 Year Forecast
  • 6MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Alpha Antitrypsin Deficiency Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Alpha Antitrypsin Deficiency market
  • Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency market
  • To understand the future market competition in the Alpha Antitrypsin Deficiency market.

Table of Contents

1 Key Insights

2 Executive Summary of Alpha Antitrypsin Deficiency

3 SWOT Analysis for Alpha Antitrypsin Deficiency

4 Patient Share of Alpha Antitrypsin Deficiency at a Glance

  • 4.1 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
  • 4.2 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

5 Alpha Antitrypsin Deficiency Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2017
  • 5.2 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2030

6 Disease Background and Overview

  • 6.1 Introduction
  • 6.2 Symptoms
  • 6.3 Etiology
  • 6.4 Risk Factors
  • 6.5 Genetic Inheritance of AAT Deficiency
  • 6.6 Clinical Manifestations
  • 6.7 Pathophysiology
  • 6.8 Biomarkers
  • 6.9 Diagnosis
  • 6.1 Diagnostic Delay

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM

8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency

  • 8.1 Assumptions and Rationale: 6MM
  • 8.2 United States
    • 8.2.1 Prevalence of Symptomatic AATD in the United States
    • 8.2.2 Diagnosed population of AATD in the United States
    • 8.2.3 Genotype of AATD Diagnosed patients in the United States
    • 8.2.4 Comorbidity associated with AATD in the United States
  • 8.3 EU5
    • 8.3.1 Germany
      • 8.3.1.1 Prevalence of Symptomatic AATD in Germany
      • 8.3.1.2 Diagnosed population of AATD in Germany
      • 8.3.1.3 Genotype of AATD Diagnosed patients in Germany
      • 8.3.1.4 Comorbidity associated with AATD in Germany
    • 8.3.2 France
      • 8.3.2.1 Prevalence of Symptomatic AATD in France
      • 8.3.2.2 Diagnosed population of AATD in France
      • 8.3.2.3 Genotype of AATD Diagnosed patients in France
      • 8.3.2.4 Comorbidity associated with AATD in France
    • 8.3.3 Italy
      • 8.3.3.1 Prevalence of Symptomatic AATD in Italy
      • 8.3.3.2 Diagnosed population of AATD in Italy
      • 8.3.3.3 Genotype of AATD Diagnosed patients in Italy
      • 8.3.3.4 Comorbidity associated with AATD in Italy
    • 8.3.4 Spain
      • 8.3.4.1 Prevalence of Symptomatic AATD in Spain
      • 8.3.4.2 Diagnosed population of AATD in Spain
      • 8.3.4.3 Genotype of AATD Diagnosed patients in Spain
      • 8.3.4.4 Comorbidity associated with AATD in Spain
    • 8.3.5 United Kingdom
      • 8.3.5.1 Prevalence of Symptomatic AATD in the United Kingdom
      • 8.3.5.2 Diagnosed population of AATD in the United Kingdom
      • 8.3.5.3 Genotype of AATD Diagnosed patients in the United Kingdom
      • 8.3.5.4 Comorbidity associated with AATD in the United Kingdom

9 Treatment

  • 9.1 Current therapies
    • 9.1.1 Augmentation Therapy
    • 9.1.2 Gene Therapy strategies
    • 9.1.3 Lifestyle Changes
    • 9.1.4 Novel therapeutics

10 Treatment Algorithm

  • 10.1 Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
  • 10.2 Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

11 Unmet Needs

12 Organizations contributing toward Alpha Antitrypsin Deficiency

13 Case Reports

  • 13.1 An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
  • 13.2 The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
  • 13.3 A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

14 Marketed Drugs

  • 14.1 Prolastin C: Grifols
    • 14.1.1 Drug Description
    • 14.1.2 Mechanism of Action
    • 14.1.3 Regulatory Milestones
    • 14.1.4 Advantages and Disadvantages
    • 14.1.5 Safety and Efficacy of Prolastin-C
  • 14.2 Glassia: Kamada
    • 14.2.1 Drug Description
    • 14.2.2 Mechanism of Action
    • 14.2.3 Regulatory Milestones
    • 14.2.4 Advantages and Disadvantages
    • 14.2.5 Safety and Efficacy of Glassia
  • 14.3 Aralast: Shire
    • 14.3.1 Drug Description
    • 14.3.2 Mechanism of Action
    • 14.3.3 Regulatory Milestones
    • 14.3.4 Advantages and Disadvantages
    • 14.3.5 Safety and Efficacy of Aralast
  • 14.4 Zemaira: CSL Behring
    • 14.4.1 Drug Description
    • 14.4.2 Mechanism of Action
    • 14.4.3 Regulatory Milestones
    • 14.4.4 Advantages and Disadvantages
    • 14.4.5 Safety and Efficacy of Zemaira
  • 14.5 Alfalastin: LFB Biotechnologies
    • 14.5.1 Description
    • 14.5.2 Regulatory Milestones
    • 14.5.3 Advantages and Disadvantages
    • 14.5.4 Safety and Efficacy
  • 14.6 Trypsone: Grifols
    • 14.6.1 Description
    • 14.6.2 Regulatory Milestones
    • 14.6.3 Advantages and Disadvantages
    • 14.6.4 Efficacy and Safety

15 Emerging Therapies

  • 15.1 Inhaled AAT (Glassia IH): Kamada Ltd
    • 15.1.1 Product Description
    • 15.1.2 Regulatory Milestones
    • 15.1.3 Product Development Activities
    • 15.1.4 Clinical Development
      • 15.1.4.1 Clinical Trials Information
    • 15.1.5 Safety and Efficacy
  • 15.2 ALN-AAT02: Alnylam Pharmaceuticals
    • 15.2.1 Product Description
    • 15.2.2 Product Development Activities
    • 15.2.3 Clinical development
      • 15.2.3.1 Clinical Trials Information
    • 15.2.4 Safety and Efficacy
  • 15.3 ARO-AAT: Arrow Head Pharmaceuticals
    • 15.3.1 Product Description
    • 15.3.2 Product Development Activities
    • 15.3.3 Clinical Development
      • 15.3.3.1 Clinical Trials Information
    • 15.3.4 Safety and Efficacy
  • 15.4 VX-814: Vertex Pharmaceuticals
    • 15.4.1 Product Description
    • 15.4.2 Product Development Activities
    • 15.4.3 Clinical Development
      • 15.4.3.1 Clinical Trials Information
  • 15.5 Alvelestat (MPH-966): Mereo Biopharma
    • 15.5.1 Product Description
    • 15.5.2 Product Development Activities
    • 15.5.3 Clinical Development
      • 15.5.3.1 Clinical Trials Information
  • 15.6 DCR-A1AT: Dicerna Pharmaceuticals
    • 15.6.1 Product Description
    • 15.6.2 Product Development Activities
    • 15.6.3 Clinical Development
      • 15.6.3.1 Clinical Trial Information
    • 15.6.4 Pre-clinical Results

16 Other Promising Candidates

  • 16.1 INBRX-101: Inhibrx
    • 16.1.1 Product Description
    • 16.1.2 Product Development Activities
    • 16.1.3 Clinical development
  • 16.2 Carbamazepine: Novartis Pharmaceuticals
    • 16.2.1 Product Description
    • 16.2.2 Clinical Development
      • 16.2.2.1 Clinical Trials Information
  • 16.3 VX-864: Vertex Pharmaceuticals
    • 16.3.1 Product Description

17 Alpha Antitrypsin Deficiency: 6 Major Market Analysis

  • 17.1 Total Market Size of AATD

18 Alpha Antitrypsin Deficiency: Country-Wise Market Analysis

  • 18.1 United States
    • 18.1.1 Total Market Size of AATD
    • 18.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in United States
  • 18.2 EU-5
    • 18.2.1 Germany
      • 18.2.1.1 Total Market Size of AATD in Germany
      • 18.2.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in Germany
    • 18.2.2 France
      • 18.2.2.1 Total Market Size of AATD in France
      • 18.2.2.2 Market Size of Alpha Antitrypsin Deficiency by Products in France
    • 18.2.3 Italy
      • 18.2.3.1 Total Market Size of AATD in Italy
      • 18.2.3.2 Market Size of Alpha Antitrypsin Deficiency by Products in Italy
    • 18.2.4 Spain
      • 18.2.4.1 Total Market Size of AATD in Spain
      • 18.2.4.2 Market Size of Alpha Antitrypsin Deficiency by Products in Spain
    • 18.2.5 United Kingdom
      • 18.2.5.1 Total Market Size of AATD in The UK
      • 18.2.5.2 Market Size of Alpha Antitrypsin Deficiency by Products in UK

19 Grifols Initiatives towards Alpha Antitrypsin deficiency

20 US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

21 Market Drivers

22 Market Barriers

23 Access and Reimbursement Overview of Alpha Antitrypsin Deficiency

  • 23.1 The Italian Experience
  • 23.2 Augmentation Therapy - slowly finding its way in the UK
  • 23.3 The Changing Future

24 Appendix

  • 24.1 Bibliography
  • 24.2 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight